Bristol-Myers Squibb has patented substituted triazolylpyridine derivative compounds for treating cancer by modulating histone demethylase enzymes. The method involves inhibiting specific enzymes like FBXL10, JARID1B, JMJD2C, and JMJD3 with the compound of Formula II. GlobalData’s report on Bristol-Myers Squibb gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Bristol-Myers Squibb Co - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bristol-Myers Squibb, Cancer treatment biomarkers was a key innovation area identified from patents. Bristol-Myers Squibb's grant share as of January 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11884648B2) discloses a method for inhibiting histone demethylase enzymes, specifically targeting enzymes such as FBXL10, JARID1B, JMJD2C, and JMJD3. The method involves contacting the histone demethylase enzyme with a compound of Formula II, which has a specific chemical structure designed to inhibit the enzyme's activity. This innovative approach offers a potential solution for regulating gene expression by targeting specific histone demethylase enzymes.

In the disclosed method, the compound of Formula II includes specific structural features, such as R2 being chloro or fluoro, and R4 and R5 being hydrogen while R3 is aralkyl optionally substituted with halogen or alkyl, or cycloalkyl. The patent claims also specify the exact structure of the compound required for inhibiting the histone demethylase enzymes effectively. By providing a detailed description of the chemical composition and the method of application, this patent opens up new possibilities for developing targeted therapies that can modulate gene expression by inhibiting histone demethylase enzymes. This advancement in the field of epigenetics could have significant implications for various areas of research, including cancer treatment and gene regulation mechanisms.

To know more about GlobalData’s detailed insights on Bristol-Myers Squibb, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies